For laboratory research purposes only. Not for human consumption.
Belgian researchers sourcing peptide compounds for in-vitro and preclinical studies are working in a market that shifted noticeably over the past year. Peptide Sciences, one of the most-cited US benchmark suppliers, voluntarily discontinued all operations on 6 March 2026. That closure removed a common reference point for the research community and pushed demand toward EU-based alternatives that ship without customs delays. This guide covers what actually matters in that sourcing decision for Belgium: the legal framework, COA standards, logistics, and the criteria that separate genuine research-grade suppliers from the rest.
Is It Legal to Buy Research Peptides in Belgium?
Synthetic peptides sold as research chemicals sit at the intersection of two Belgian regulatory frameworks, and knowing which one applies is what makes sourcing compliant. Because Belgium is officially trilingual (Dutch, French, German), its institutions and statutes carry parallel names, and this guide gives both the Dutch and French forms where relevant.
The medicines framework (Law of 25 March 1964). Belgium’s principal medicines statute, the Law of 25 March 1964 on medicines, sets the framework for medicinal products for human use, transposing the EU rules of Directive 2001/83/EC. Broadly, a substance is treated as a medicinal product when it is presented as having properties for treating or preventing disease, or when it is administered to restore, correct, or modify physiological functions. A peptide sold exclusively for in-vitro research, labelled “not for human consumption” and carrying no therapeutic claims, generally falls outside that definition. Classification turns on presentation, composition, and intended use, so the label alone is not an automatic exemption. Medicines advertising in Belgium is regulated by the Royal Decree of 7 April 1995 and enforced by the Federal Agency for Medicines and Health Products: in Dutch the Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten (FAGG), in French the Agence fédérale des médicaments et des produits de santé (AFMPS), commonly cited in English by the acronym FAMHP. The agency was established on 1 January 2007 and is the licensing and pharmacovigilance authority for medicines in Belgium.
The controlled-substances framework (Law of 24 February 1921 + Royal Decree of 6 September 2017). Belgium’s narcotics and psychotropics regime rests on the Law of 24 February 1921 on the trade in poisonous, soporific, narcotic, psychotropic, disinfectant and antiseptic substances, with the detailed lists set out in the Royal Decree of 6 September 2017 regulating narcotic and psychotropic substances. The FAMHP administers this regime through its dedicated narcotics function. Standard research peptides such as BPC-157, TB-500, GHK-Cu, Epitalon, Selank, Ipamorelin, and most growth hormone secretagogues are not the scheduled narcotic or psychotropic substances this framework targets. Working with scheduled substances for scientific purposes requires specific administrative authorisation from the FAMHP, but that regime does not reach unscheduled research peptides.
Two areas carry elevated risk:
GLP-1 class compounds. Semaglutide, tirzepatide, and liraglutide are authorised medicinal substances in Belgium and carry elevated regulatory and import scrutiny. Any framing that presents them as therapeutic alternatives to prescription medicines brings them within the medicines framework and its advertising rules, which the FAMHP actively enforces. Framing must stay strictly scientific, and researchers should confirm import and handling requirements through their own institution.
Novel compounds. The schedules under the Royal Decree of 6 September 2017 are subject to update, and newer psychoactive compounds can be added; a 2017 reform was specifically designed to make it easier to bring synthetic substances under control. Researchers should verify the current status of any novel compound before ordering.
In practice: Belgian customs is the General Administration of Customs and Excise (in Dutch the Algemene Administratie van de Douane en Accijnzen, in French the Administration générale des douanes et accises), part of the Federal Public Service Finance. It generally treats shipments moving within the EU as internal-market movements rather than dutiable imports. Such intra-EU movements are generally not subject to import duties or routine inspection, though restricted, mislabelled, or unlawful goods can still be stopped. Orders arriving from outside the EU may be examined and held.
Why EU-Domestic Shipping Matters for Belgian Researchers
Belgium is a founding EU member and sits inside the EU customs union, where customs duties between member states are prohibited and goods that have entered free circulation move without internal tariffs or routine border checks (TFEU Articles 28-30). Suppliers with EU-based warehouses ship peptide orders without the customs delay, documentation burden, or seizure risk that affect shipments arriving from outside the EU. Typical delivery windows from EU warehouses to Belgium:
- Western/Central EU (Romania, Slovakia, Czech Republic): 2–4 business days
- Northern EU (Baltic states): 3–5 business days
- UK-based suppliers: subject to EU import controls post-Brexit; 5–10+ days with variable customs outcomes
For time-sensitive research protocols or compounds that benefit from a short transit, EU-domestic shipping is strongly preferred. Belgium’s central position and dense logistics network (the ports of Antwerp and Zeebrugge, plus Brussels and Liège air hubs) means intra-EU parcels typically clear quickly.
How to Evaluate a Research Peptide Supplier: The COA Standard
A Certificate of Analysis (COA) is the central quality document in research peptide procurement. Its evidentiary value depends entirely on who produced it and how.
The minimum acceptable COA
An acceptable third-party COA for research-grade peptides must include:
- HPLC purity (%): High-Performance Liquid Chromatography with the chromatogram included. Purity should be 98% or higher for research-grade material; 99%+ is achievable and increasingly common among quality suppliers.
- Identity confirmation via LC-MS (Liquid Chromatography-Mass Spectrometry): the observed molecular mass must match the theoretical mass of the named peptide within standard instrument tolerance.
- Lot/batch number matching exactly what is printed on the vial. A COA from a different batch is not a COA for what was received.
- Testing laboratory name, address, and date. Independent labs issue reports on letterhead with contact information. Requests to “contact us for the COA” without a document are a red flag.
- No commercial relationship to the supply chain. The lab must not be owned by, operated by, or co-located with the manufacturer or vendor.
Janoshik Analytical: the EU research peptide reference lab
Janoshik Analytical (Czech Republic) has become the most widely used third-party testing laboratory for research peptides in the European market. Their standard report includes HPLC purity, LC-MS identity confirmation, and amino acid composition where applicable. Reports are issued with a unique report number that can be referenced in procurement documentation.
Extended COA parameters
Some EU suppliers now provide expanded COA packages: endotoxin testing (LAL assay), bioburden (microbial limit testing), heavy-metal screening (ICP-MS), and residual-solvent testing. These parameters matter for cell-culture and small-animal research where contamination artefacts could confound results. If your protocol is sensitivity-limited, request these extended parameters before ordering.
Sourcing Criteria Checklist for Belgian Research Institutions
For researchers at Belgian universities (KU Leuven, Ghent University, UCLouvain, ULB, University of Antwerp, VUB, University of Liège), research institutes such as VIB or Sciensano, or pharmaceutical companies ordering peptides for non-clinical studies, a standardised supplier-evaluation process reduces both quality risk and administrative overhead:
- COA on product page: independent third-party, correct lot number, HPLC + LC-MS minimum
- EU warehouse: confirmed EU-domestic shipping origin
- Delivery timeline documented: a stated SLA for Belgium specifically, not a generic “EU” figure
- Packaging standard: lyophilised vials in sealed glass, shipped with temperature-appropriate packaging
- Reconstitution documentation, covering bacteriostatic water compatibility, storage temperature (typically −20°C long-term), and solubility notes (aqueous vs organic solvent)
- Legal compliance statement: “for research use only, not for human consumption” on product page and packaging
- Invoice/documentation: commercial invoice for institutional procurement records, VAT-compliant billing
What Belgian Researchers Are Ordering in 2026
Research peptide classes commonly available to and studied by researchers sourcing from Belgium in 2026 include:
Healing and tissue-biology research: BPC-157, TB-500 (Thymosin Beta-4), and their combination. Both are stable compounds with well-characterised HPLC profiles, so COA verification tends to be straightforward, and the published preclinical literature is extensive.
Metabolic and receptor-biology research: GLP-1 class compounds (semaglutide, tirzepatide, retatrutide) for receptor pharmacology, islet-cell biology, and adipocyte studies. Note: these require strict research-only framing in all procurement and lab documentation.
Longevity and telomere-biology research: Epitalon (tetrapeptide), GHK-Cu (copper peptide), MOTS-c (mitochondrial-derived peptide). Interest in this cluster has grown following several high-profile publications.
Nootropic and CNS research: Selank, Semax, Dihexa. Academic interest in these neuropeptides has grown as source data from Eastern European research institutions becomes more accessible.
Growth-hormone-axis research: Ipamorelin, CJC-1295, Sermorelin, Hexarelin. Used in pituitary-axis studies and GH-pulse characterisation experiments.
Storage and Handling for Research-Grade Peptides
Proper storage preserves peptide integrity and analytical validity. Standard protocols for lyophilised (freeze-dried) research peptides:
- Long-term storage: −20°C in the original sealed vial, protected from moisture and light
- Working aliquot (post-reconstitution): 4°C refrigerated, typically stable 2–4 weeks depending on the peptide
- Reconstitution vehicle: bacteriostatic water is standard for most peptides; 0.1% acetic acid is used for GH-releasing peptides (GHRP class) with poor aqueous solubility. Low-concentration dimethyl sulfoxide (DMSO) is used for select hydrophobic peptides, so confirm with the supplier’s reconstitution guide.
- Cycle count: minimise freeze-thaw cycles. Single-use aliquots are recommended for sensitive assays.
All storage notes above describe laboratory handling protocols for research compounds. They do not constitute instructions for human use.
Key Questions to Ask Any Supplier Before Ordering
- Which independent laboratory performed the COA, and what was the lot number tested?
- Can you provide the full COA document, rather than only the purity figure, before I place an order?
- Where is your EU warehouse located, and what is the expected delivery time to [Belgian city or postal code]?
- Do you ship with cold-chain packaging for GLP-1 class peptides?
- What is your re-test policy if a received vial shows evidence of degradation?
- Is your packaging labelled for research use only, with no human-use language?
Summary
Belgian researchers have access to a well-developed EU market for research-grade peptides. The legal picture is defined by two frameworks: the medicines regime under the Law of 25 March 1964 (administered by the FAMHP / FAGG / AFMPS) and the controlled-substances regime under the Law of 24 February 1921 and the Royal Decree of 6 September 2017. In practice the differentiators are COA quality (independent third-party, lot-matched, HPLC+MS minimum), EU-domestic shipping logistics, and strict research-only framing. Suppliers with transparent, publicly posted COAs and EU-based inventory are the appropriate starting point for institutional and academic procurement decisions.
CertaPeptides ships from within the EU to Belgium, posts full Janoshik COA documents on every product page, and labels all compounds for research use only. No human-use claims are made.
This article is for research information purposes only. All compounds referenced are supplied exclusively as research chemicals for laboratory use, not as medicinal products, and are not intended for human or animal use. Some compounds named (for example semaglutide and tirzepatide) are active substances in separately authorised medicines; CertaPeptides supplies only research-grade chemicals and makes no therapeutic claims.